Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
Protalix Fabry Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
06:09pm, Tuesday, 12'th May 2020
Protalix reported positive data from its Fabry disease trial. AtriCure reported positive data from its CONVERGE Study. Oyster Point Pharma reported mixed toplin
Edited Transcript of ATRC earnings conference call or presentation 29-Apr-20 8:30pm GMT
07:49am, Tuesday, 12'th May 2020
Q1 2020 AtriCure Inc Earnings Call
AtriCure Announces Pricing of Public Offering of Common Stock
12:10am, Tuesday, 12'th May 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of
AtriCure Announces Pricing of Public Offering of Common Stock
12:00am, Tuesday, 12'th May 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
06:02pm, Monday, 11'th May 2020
Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
AtriCure Announces Proposed Public Offering of Common Stock
11:16am, Monday, 11'th May 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten pub
AtriCure Announces Proposed Public Offering of Common Stock
12:00am, Monday, 11'th May 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
The Top Stocks To Buy Now
12:41am, Saturday, 09'th May 2020
Individual stock picking is increasingly important. Continue to concentrate on healthcare and technology. Here are the top stocks to buy now.
AtriCure Announces Results from CONVERGE IDE Clinical Trial
12:47pm, Friday, 08'th May 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the results from the CONVERGE IDE clinical t
May 08, 2020 Xherald --
Global Atrial Appendage Occluder Market, delivering a must-read report for industry stakeholders wanting to understand the strategic...
AtriCure Announces Results from CONVERGE IDE Clinical Trial
12:00am, Friday, 08'th May 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
Q1 2020 Earnings Forecast for AtriCure Inc. (NASDAQ:ATRC) Issued By SVB Leerink
06:22am, Saturday, 02'nd May 2020
AtriCure Inc. (NASDAQ:ATRC) – SVB Leerink increased their Q1 2020 earnings estimates for shares of AtriCure in a report released on Tuesday, April 28th. SVB Leerink analyst D. Antalffy now anticipat
